Hugues Bienaymé

ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France.

Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC.

Chrysalon SA is a French company that researches and develops medicinal chemical products and pharmaceuticals. The company is based in Villeurbanne, France. Chrysalon was acquired by Urogene SA on March 31, 2002.